Literature DB >> 9605749

Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants.

A Albor1, S Kaku, M Kulesz-Martin.   

Abstract

p53-interacting proteins from mouse epidermal cells and human myelogenous leukemia cells were isolated by affinity chromatography using glutathione S-transferase (GST)-p53 fusion proteins. One of these proteins was topoisomerase I, whose interaction with p53 was recently reported. A carboxyl-terminal fragment containing the last 92 amino acids of p53 (GST-299-390) was sufficient for binding to topoisomerase I. Nanomolar concentrations of either GST-p53 or GST-299-390 enhanced the catalytic activity of purified human topoisomerase I. Purified wild-type human p53 and point mutants Ser-239, Ser-245, and His-273 were equivalent in their enhancement of human topoisomerase I activity. Because topoisomerase I is thought to promote genetic recombination, competence to enhance topoisomerase I catalytic activity coupled with a deficiency in transcriptional activity may be a mechanism for gain of function in mutant p53 proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro.

Authors:  Holger Stephan; Frank Grosse; Kent Søe
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

4.  p53 stimulates human topoisomerase I activity by modulating its DNA binding.

Authors:  Kent Søe; Frank Grosse
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

5.  Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.

Authors:  S Kaku; Y Iwahashi; A Kuraishi; A Albor; T Yamagishi; S Nakaike; M Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

6.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 7.  DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Authors:  A K Larsen; C Gobert
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

8.  Identification of critical amino acid residues on human dihydrofolate reductase protein that mediate RNA recognition.

Authors:  Ningwen Tai; Yuyan Ding; John C Schmitz; Edward Chu
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

Review 9.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

10.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.

Authors:  U P Kelavkar; K F Badr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.